Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
苏州吉美瑞生医学科技有限公司 logo — Pioneering the future of regenerative medicine with the worl...

苏州吉美瑞生医学科技有限公司

Pioneering the future of regenerative medicine with the world’s first autologous stem cell treatment for respiratory diseases.

Founded 2015 5 employees Series B Total: $100.00M Biotechnology, Health Care +1

General Information

Company Name 苏州吉美瑞生医学科技有限公司
Founded Year 2015
Employees 5
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series B
Social

Get notified when 苏州吉美瑞生医学科技有限公司 moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About 苏州吉美瑞生医学科技有限公司

Suzhou Jimray Biotechnology Co., Ltd. is pioneering the future of regenerative medicine with its flagship product, REGEND001 cell preparation, the world's first autologous stem cell solution for respiratory diseases. Established in 2015, the company has received approval from the State Food and Drug Administration and is registered by both the National Health and Family Planning Commission and the Food and Drug Administration for clinical stem cell research. The firm has also garnered support from the Ministry of Science and Technology for its key research and development programs. With ISO9001:2008 quality management system certification and various accreditations, Suzhou Jimray Biotechnology is devoted to adhering to stringent regulatory standards. The company's visionary approach has attracted a CNY100.00M Series B investment on March 3, 2022, from prominent investors including Shenzhen Capital Group, Soochow Securities Co., Ltd., China Merchants Securities, and Wanrong Hongtu Fund. As a leader in the biotechnology, health care, and health and wellness industries, Suzhou Jimray Biotechnology is poised to make significant strides in the field of regenerative medicine.

Taxonomy: regenerative medicine, stem cell treatment, respiratory diseases, autologous stem cells, medical approvals, clinical research, Ministry of Science and Technology endorsement, quality management system, China healthcare regulations, global leader, ISO certification, regulatory compliance, organ regeneration, healthcare advancements

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 4
Investor Investor
•••• •••• 		03 Mar 2022

苏州吉美瑞生医学科技有限公司 Alternatives & Competitors

苏州吉美瑞生医学科技有限公司 vs
Inheritor Cell Technology
Inheritor Cell Technology United States

"The key to every biological problem must finally be sought in the cell"​ -Edmund Beecher Wilson

3 employees
Biotechnology, Pharmaceutical
苏州吉美瑞生医学科技有限公司 vs
BRL Medicine 邦耀生物
BRL Medicine 邦耀生物 China

Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whol...

Series B
12 employees
Biopharma, Biotechnology
苏州吉美瑞生医学科技有限公司 vs
Stempeutics Research Private Limited
Stempeutics Research Private Limited India

An innovative life science company focused on developing & commercializing novel therapeutics based...

48 employees
Biotechnology, Health Care

FAQ About 苏州吉美瑞生医学科技有限公司

Pioneering the future of regenerative medicine with the world’s first autologous stem cell treatment for respiratory diseases.
苏州吉美瑞生医学科技有限公司 was founded in 2015.
苏州吉美瑞生医学科技有限公司 operates in the following industries: Biotechnology, Health Care, Health and Wellness.
苏州吉美瑞生医学科技有限公司 has approximately 5 employees.
苏州吉美瑞生医学科技有限公司 has completed 1 funding round, raising a total of $100.00M. The latest funding stage is Series B.
Top alternatives and competitors to 苏州吉美瑞生医学科技有限公司 include Inheritor Cell Technology, BRL Medicine 邦耀生物, Stempeutics Research Private Limited, Anagenesis Biotechnologies, CorrectSequence Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
苏州吉美瑞生医学科技有限公司 and Inheritor Cell Technology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors 苏州吉美瑞生医学科技有限公司 and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes